Compare CTGO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | ZURA |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.2M | 455.4M |
| IPO Year | 2010 | N/A |
| Metric | CTGO | ZURA |
|---|---|---|
| Price | $16.41 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $41.00 | $13.00 |
| AVG Volume (30 Days) | 380.7K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.50 | $1.35 |
| 52 Week High | $34.38 | $7.25 |
| Indicator | CTGO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 56.11 |
| Support Level | $14.96 | $5.17 |
| Resistance Level | $17.92 | $5.88 |
| Average True Range (ATR) | 0.85 | 0.39 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 41.18 | 68.60 |
Contango Silver & Gold Inc, formerly Contango Ore Inc operates in the United States. The company is engaged in the exploration for and development of gold ore and associated minerals in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin, whose governmental entity is the Tetlin Tribal Council, for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.